about
The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinomaBenign schwannoma in paranasal sinuses: a clinico-pathological study of five cases, emphasising diagnostic difficulties.Randomized controlled trial to assess the effectiveness of a videotape about radiotherapy.Carotid dosimetry for T1 glottic cancer radiotherapy.Metastatic renal cell carcinoma to the nose and paranasal sinuses.Carcinoma of the hard palate treated with radiotherapy: a retrospective review of 31 cases.Radiotherapy treatment of non-melanoma skin cancer: a survey of current UK practice and commentaryAdaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancerStromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma.Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 casesEvaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: a retrospective review.Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers.Management of lateral skull base cancer: United Kingdom National Multidisciplinary Guidelines.Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review.The impact of radiotherapy on swallowing and speech in patients who undergo total laryngectomy.Collagen vascular diseases and enhanced radiotherapy-induced normal tissue effects--a case report and a review of published studies.Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre.Indications for Salivary Gland Radiotherapy.An automated workflow for patient-specific quality control of contour propagation.Prediction of post-treatment trismus in head and neck cancer patients.Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer.Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk.Radical radiotherapy for carcinoma of the vulva.Conventional fractionation should not be the standard of care for T2 glottic cancer.Value of the Hospital Anxiety and Depression Scale in the follow up of head and neck cancer patients.Prognostic value of hypoxia-associated markers in advanced larynx and hypopharynx squamous cell carcinoma.Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer?Unnecessary morbidity following irradiation of lateralized head and neck carcinoma.Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.Case report: radical radiotherapy for early laryngeal cancer in a patient with human immunodeficiency virus: no evidence of increased toxicity.Lack of prognostic effect of carbonic anhydrase-9, hypoxia inducible factor-1α and bcl-2 in 286 patients with early squamous cell carcinoma of the glottic larynx treated with radiotherapy.Relative plan robustness of step-and-shoot vs rotational intensity-modulated radiotherapy on repeat computed tomographic simulation for weight loss in head and neck cancer.Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy.Quality of life measurement in the head and neck cancer radiotherapy clinic: is it feasible and worthwhile?Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.Late radiation change in the CNS: MR imaging following gadolinium enhancement.Practice Change after Evaluation of an Offline Correction Protocol for Image-guided Radiotherapy in Head and Neck Cancer.Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
P50
Q28296020-65338100-407C-42ED-8496-CDAC21340B8AQ33294529-64966BE1-75DD-438E-B0AF-C2E235F7D8B7Q33389661-59B0D09D-362F-41EC-BDA5-F75C9B7C78CBQ33823152-301C73AC-DA0D-412A-A1FE-B5EFB04000B2Q34043369-CE96019F-2C02-4B88-88D7-6860F086A56DQ34297855-9E908032-4E10-4B41-BBD2-E34E14D98784Q34392052-C890E694-A9E0-4D43-9C4B-89D3A5C6A501Q34596781-B36F578C-DA4E-46A3-A8EA-5E8E99DB034CQ36081369-EA758074-332C-45FD-AF40-64BFC4881571Q36116443-A42ECB32-E2A0-4852-846A-0991570F7AC4Q36391297-5004E0D7-A34F-4980-B7A7-939BE5A1E6DFQ36498623-4858FF60-86C8-4366-9147-2B6BD08FC43CQ36620361-B15BBEF4-96EF-414B-94E8-DF038EE80BC1Q36919602-96ADFE6F-8C54-4C18-8324-6414884159C0Q36947178-3B4DD3CF-C851-4552-8399-FC3499935779Q37337372-5BBBC73F-0FB2-40DE-A5B6-95398E99B209Q37822113-9C4142A4-81E3-4F74-8D5D-F71D9F18A055Q38075639-219E6127-144D-43B9-96C6-BD52AA8225CCQ38811865-29CA4C3F-01F1-4725-9ECF-A531C6A3C043Q39018212-77189016-EBCF-4F6E-9FF0-75B67C8E0B38Q39724154-BD546915-B040-4B8B-BD62-9054F6223781Q40077574-660011CC-45BF-4EE4-89EF-943EFECDD1A1Q40396118-97168BC8-F1A7-4C25-B8C4-50D186CF7ADCQ41891737-6724CF60-EF3D-4540-937A-DA81DFCD42D0Q42505399-51273B47-4964-4F03-B113-B93E94923576Q43726687-6752CCC9-1ECF-4329-AE55-E8E1349F7563Q44247043-249E3409-EF5C-4CEB-B3BA-1A69A0284C8BQ44565372-7DBA9A5C-6F7F-44EE-930D-6F8851845E21Q44615768-BDAB0EB3-0AED-46AB-BA96-9149E650FF6DQ44665884-06140D36-AFC1-410E-8D30-A5652ABC544AQ44831795-9AA69CA9-4FF4-4443-9873-172FC66C866DQ45638611-C3131347-1EF4-4263-A892-C519D760CF43Q46115453-7B893CFB-288F-46F0-8F82-71FD32FB2CBCQ47317229-E4F8DE6F-70B0-454B-A69D-7040415DB091Q47336175-A15D0D9F-B33E-419C-AA86-F361623E19E9Q47778757-F660164B-F6B9-46AF-A681-2AFC34FBB0B5Q48063894-F392B062-6A3E-4116-BA57-2CA5E89942C3Q48715468-3721B767-8159-4720-B205-8E7AF0F3F582Q48763676-F67FC042-49C8-485B-87D3-D7B7632D5ECCQ49986900-117CA9A9-A1F7-4F1F-91AC-D4D2C699A22B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicholas J Slevin
@ast
Nicholas J Slevin
@en
Nicholas J Slevin
@es
Nicholas J Slevin
@nl
type
label
Nicholas J Slevin
@ast
Nicholas J Slevin
@en
Nicholas J Slevin
@es
Nicholas J Slevin
@nl
prefLabel
Nicholas J Slevin
@ast
Nicholas J Slevin
@en
Nicholas J Slevin
@es
Nicholas J Slevin
@nl
P106
P1153
7003789638
P21
P31
P496
0000-0002-3367-7013